Trzenschik K, Schmidt U J, Abendroth K, Ansorg H, Graner H, Lindenhayn K, Schramm G, Kalbe I
Z Alternsforsch. 1978;33(5):441-51.
Sixteen patients with Paget's disease of bone aged from 51 to 80 years was treated daily with 20 micrograms (equivalent to 80 MRCU) synthetic salmon calcitonin. Fourteen patients was observed on a long time. In all cases was observed significant reductions in increased serum alkaline phosphatase. The urinary hydroxyproline excretion was also decreased. Other laboratory dates as serum calcium, serum phosphorus, serum acide phosphatase, urinary calcium and phosphorus excretion was not significantly influenced by the therapy. The treatment produced a clear remission of pain. After treatment of 6 months the dose was reduced (2 or 3 injections subcutaneously of 20 micrograms salmon calcitonin weekly). There was observed a recurrence of pain and an increase of serum alkaline phosphatase, but not until the pretreatment values. These results confirm the effectiveness of calcitonin treatment in Paget's disease of bone.
16例年龄在51至80岁之间的骨佩吉特病患者,每天接受20微克(相当于80 MRCU)的合成鲑鱼降钙素治疗。对14例患者进行了长期观察。在所有病例中,均观察到血清碱性磷酸酶升高显著降低。尿羟脯氨酸排泄也减少。其他实验室指标,如血清钙、血清磷、血清酸性磷酸酶、尿钙和磷排泄,未受到该治疗的显著影响。该治疗使疼痛明显缓解。治疗6个月后,剂量降低(每周皮下注射2次或3次20微克鲑鱼降钙素)。观察到疼痛复发和血清碱性磷酸酶升高,但未达到治疗前水平。这些结果证实了降钙素治疗骨佩吉特病的有效性。